NasdaqGS:IBRXBiotechs
ImmunityBio’s Anktiva sBLA Review Puts Bladder Cancer Thesis To Test
ImmunityBio (NasdaqGS:IBRX) received FDA acceptance for review of its supplemental Biologics License Application for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer with papillary disease.
The company also released new comparison data indicating improved efficacy and safety of ANKTIVA plus BCG versus other approved bladder cancer therapies, presented at a major medical meeting.
These developments relate to a potential expansion of ANKTIVA's approved use and could...